SUICIDALITY AND ANTIDEPRESSANT DRUGS
See full prescribing information for complete boxed warning.
- TRADE NAME: Viibryd (Merck KGaA)
- INDICATIONS: Major depressive disorder
- CLASS: Antidepressant, Serotonin-norepinephrine reuptake inhibitor
- HALF-LIFE: 25 hours
- FDA APPROVAL DATE: 01/21/2011
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Anticoagulants, Aspirin, Buspirone, CNS-active agents, CYP3A4 inhibitors or inducers, Efavirenz, Erythromycin, Ketoconazole, MAO inhibitors, NSAIDs, SNRIs, SSRIs, Tramadol, Triptans, Tryptophan, Warfarin
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Page last updated 07/31/2023
